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Introduction: Detection of bone marrow micrometastasis (BMM) 
has been focused on as a prognostic parameter in various malignant 
neoplasms recently. This study was designed to evaluate the prognos-
tic significance of BMM detection in patients with operable esopha-
geal squamous cell carcinoma (ESCC) after long-term follow-up.
Methods: In 61 consecutive patients with ESCC who had undergone 
radical surgical resection, BMM was detected through reverse tran-
scriptase-polymerase chain reaction (RT-PCR). Correlation between 
BMM detection and prognosis of the 61 patients was analyzed.
Results: BMM was found in 13 patients (21.3%). No significant cor-
relation between BMM detection and tumor, node, metastasis (TNM) 
stage was found. The median survival time, 5-year overall survival 
rate, 5-year disease-free survival rate, and 5-year distant disease-free 
survival rate for cases with positive BMM were 13.0 months, 15.4%, 
7.7%, and 34.2%, respectively, compared with that of 66.0 months, 
59.7%, 49.1%, and 60.6% for cases with negative BMM (p < 0.05). 
In multivariate analysis, BMM were found to be an independent 
factor in the prediction of overall survival (odds ratio [OR] 3.928, 
p = 0.001), disease-free survival (OR 4.285, p < 0.001), and distant 
disease-free survival (OR 3.270, p = 0.013).
Conclusions: BMM is an independent prognostic factor in the pre-
diction of the subsequent development of metastatic disease and 
disease outcome for operable ESCC patients, and may be a useful 
adjunct to conventional tumor staging. Further studies are required 
to evaluate the value of neoadjuvant or adjuvant systemic therapy in 
ESCC patients with BMM.
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(J Thorac Oncol. 2014;9: 1207–1213)
Esophageal cancer is the eighth most common cancer world-wide.1 Surgery remains the mainstay of treatment for 
resectable disease, but the prognosis for patients treated by sur-
gery alone is poor. A significant proportion of patients under-
going potentially curative (R0) resections subsequently go on 
to relapse indicating the presence of early disseminated disease 
not apparent at the time of primary treatment.2 Although the 
conventional tumor-staging parameters can provide reliable 
information about the proportion of a population of patients 
who will experience a recurrence of the disease, these mea-
sures cannot predict which individuals will relapse after pri-
mary therapy. Thus, new parameters need to be defined to 
improve the identification of patients at a high risk for relapse, 
so that adjuvant therapy may be added to these patients.
One of the most promising parameters in this regard 
is the detection of micrometastases in bone marrow. 
Micrometastases are defined as microscopic deposits of 
malignant cells distinct from primary tumors, which have the 
capacity to develop into macroscopic disease.3 Consequently, 
detection of malignant cells in sampled bone marrow is sug-
gestive of, but not conclusive evidence of, the presence of a 
metastatic phenotype.4 The detection of bone marrow micro-
metastasis (BMM) has been described in patients of many 
cancers, such as breast cancer, gastric cancer, prostate cancer, 
colorectal cancer, lung cancer, oral cancer, esophageal cancer, 
and so on.5–15 Most of the previous studies revealed a positive 
correlation of BMM detection with relapse and metastases. 
Recently, Domschke et al.5 reported the largest single-center 
cohort of BMM detection in breast cancer patients (n = 1378) 
with the longest observation time (median 82.0 months), 
and found that patients with BMM had a significantly higher 
incidence of distant metastases, poorer overall survival, and 
disease-free survival.
We have previously reported the detection of BMM 
in a group of 61 patients with esophageal squamous cell 
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carcinoma (ESCC), and found that BMM was an independent 
predictor of a poor outcome after a short-term follow-up.16 To 
date, only one study has reported the long-term outcome of 
BMM detected at the time of surgery in operable esophageal 
cancer.15 However, most of their patients had adenocarcino-
mas (78.6%, 33 of 42). No study has been concerned with the 
long-term outcome of BMM in patients with ESCC. The aim 
of this study was to investigate the impact of BMM detected 
at the time of surgery on long-term survival in patients with 
operable ESCC.
PATIENTS AND METHODS
This study was undertaken at the Cancer Center of Sun 
Yat-Sen University and was approved by its Ethics Committee. 
Informed consent was obtained from all patients before they 
entered the study.
Patients
Sixty-one consecutive patients with ESCC who under-
went radical surgical resection between October 2006 and 
May 2007 were enrolled in this study. The medical history 
was obtained from all patients who then underwent a physi-
cal examination. A chest radiograph, barium meal, contrast 
enhanced computed tomography scan of the chest and abdo-
men, esophagoscopic biopsy, complete blood count, blood 
biochemistry analyses, and liver and renal function evalua-
tions were also performed.
Methods
The methodology relating to the detection of BMM has 
been described previously and is briefly summarized below.16 
Bone marrow was aspirated from a rib at the beginning of 
surgery. Mononuclear cells were isolated by density-gradi-
ent centrifugation using a Ficoll gradient, and then stored at 
−86°C until they were used for analysis. To detect tumor cells 
in bone marrow, we used CK19 mRNA as the marker, which is 
epithelium-specific. Expression of CK19 mRNA in the bone 
marrow was assessed through the RT-PCR, using the specific 
oligonucleotide primers which have previously been used to 
detect CK19 in other cancers.
Follow-Up
Follow-up was performed every 3 months for the first 
year and every 6 months thereafter. During each follow-up visit, 
the patients received a clinical evaluation, blood biochemistry 
examination, including that of tumor markers (squamous-cell 
carcinoma antigen, carcinoembryonic antigen), ultrasonogra-
phy, and radiograph examination. Computed tomography was 
performed every 6 months. Endoscopic examinations were 
performed when necessary. Follow-up was continued up to 
November 2013 or until death, if this occurred earlier.
Statistical Analysis
Statistical analysis was performed using SPSS 13.0 
software (SPSS Inc., Chicago, IL). Overall survival, disease-
free survival, and distant disease-free survival rates were 
analyzed. Overall survival time was calculated from the date 
of operation, to the date of death or most recent follow-up. 
Disease-free survival was defined as survival without the 
development of local recurrences or distant metastases. 
Distant disease-free survival was defined as survival without 
the development of distant metastases. Univariate analysis 
of survival was performed using the Kaplan-Meier method 
to estimate survival probabilities in patient subgroups, with 
the entry factors of gender, age (≤60 years versus >60 years), 
tumor location, histologic grade, pT category, pN category, 
pTNM stage, and BMM. The log-rank test was used to assess 
differences in survival between groups. Multivariate analysis 
was performed to investigate the prognostic factors by the Cox 
proportional hazard regression model. All statistical tests were 
performed two-sided, and a p value less than 0.05 was consid-
ered to be statistically significant.
RESULTS
Patient Characteristics
This study group contained 42 men and 19 women 
ranging in age from 35 to 75 years (median 58 years). The 
primary lesions were most often found in the middle third of 
the thoracic esophagus, with 21 well-differentiated tumors, 33 
moderately differentiated tumors, and 7 poorly differentiated 
tumors. Twenty-two of the sixty-one patients (36.1%) proved 
postoperatively to have histologically confirmed lymph node 
metastases. According to the seventh edition of the American 
Joint Committee on Cancer (AJCC) staging system for ESCC, 
the study included 3 stage Ia patients, 8 stage Ib patients, 10 
stage IIa patients, 17 stage IIb patients, 14 stage IIIa patients, 
8 stage IIIb patients, and 1 stage IIIc patients.
None of the 61 patients underwent chemotherapy or 
radiotherapy before surgery, and none had prior malignant dis-
ease or distant metastases on routine examination before sur-
gery. All 61 patients underwent transthoracic esophagectomy 
with two-field lymphadenectomy (the mediastinal and perigas-
tric lymph nodes), and all had radical resection (R0). No patient 
died during treatment in hospital and 30 days after surgery.
TABLE 1.  Correlation of BMM Detection with Tumor, 
Node, Metastasis Stage According to the Seventh Edition 
of American Joint Committee on Cancer Staging System for 
ESCC
Category
Number of 
Patients
BMM
p Value
Positive  
(%)
Negative 
(%)
pT category 0.319
  pT1-2 17 2 (11.8) 15 (88.2)
  pT3-4 44 11 (25.0) 33 (75.0)
pN category 0.193
  pN0 39 6 (15.4) 33 (84.6)
  pN1-2 22 7 (31.8) 15 (68.2)
pTNM stage 0.059
  I–II 38 5 (13.2) 33 (86.8)
  III 23 8 (34.7) 15 (65.2)
BMM, bone marrow micrometastasis; ESCC, esophageal squamous cell carcinoma.
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No patients received adjuvant chemotherapy or radio-
therapy. Palliative chemoradiotherapy was administered to 
patients with local recurrence during follow-up, whereas only 
chemotherapy was administered to those patients with distant 
metastasis.
Bone Marrow Micrometastasis
BMM was found in 13 patients (21.3%). The relation-
ship between the presence of BMM and clinicopathological 
variables based on the sixth edition of the AJCC staging sys-
tem for esophageal cancer had been summarized in the pre-
vious report.16 None of the clinicopathologic variables were 
correlated with BMM detection.
We reanalyzed our data for possible correlations between 
BMM detection and tumor, node, metastasis stage according to 
the seventh edition of AJCC staging system for ESCC. The inci-
dences of BMM detected in patients with pT1-2, pN0, and stage 
I–II were 11.8%, 15.4%, and 13.2%, respectively, compared 
with that of 25.0%, 31.8%, and 34.7% for patients with pT3-4, 
pN1-2, and stage III. Although higher rates of BMM detection 
were found in the advanced stage patients, no significant differ-
ences were observed between the groups of pT1-2 versus pT3-4, 
pN0 versus pN1-2, and stage I–II versus stage III (p > 0.05, 
Table 1). Because of the small patient numbers in our study, 
we think that further studies are needed to assess these results.
Survival and Prognostic Factors
By November 2013, with a mean follow-up of 44.1 
months (range, 1–83 months), 34 patients had died, 26 were 
still alive, and one was lost to follow-up. During follow-up, 
36 patients developed local recurrences or distant metastases. 
The first failure sites in these 36 cases included local recur-
rences in 11 cases, local recurrences with distant metastases 
in 10 cases, and distant metastases in 15 cases. The median 
time from treatment to failure was 37.0 months (95% con-
fidence interval (CI) 13.8–60.2 months). The most common 
sites of distant metastases were the lung and liver, although 
bone metastasis was found in only one case.
TABLE 2.  Univariate Analysis in Regard to Overall Survival, Disease-Free Survival, and Distant Disease-Free Survival of  
61 Patients with Esophageal Squamous Cell Carcinoma According to Patient and Tumor Characteristics
Variable No. of Patients MST (Months) 5-yr OS (%) p Value 5-yr DFS (%) p Value 5-yr DDFS (%) p Value
Gender 0.167 0.088 0.481
  Male 42 42.0 46.5 32.1 49.3
  Female 19 - 57.9 57.9 62.3
Age (yr) 0.189 0.212 0.143
  ≤60 34 43.0 41.6 30.5 43.1
  >60 27 - 59.3 51.9 67.6
Tumor location 0.269 0.244 0.513
  Upper third 4 - 75.0 75.0 75.0
  Middle third 38 36.0 41.7 33.8 49.5
  Lower third 19 66.0 61.8 45.9 57.9
Histologic grade 0.038 0.076 0.183
  Well 21 - 66.3 51.6 59.5
  Moderate 33 53.0 47.1 41.7 59.1
  Poor 7 26.0 14.3 0 0
pT category 0.109 0.054 0.145
  pT1 7 - 85.7 85.7 85.7
  pT2 10 66.0 60.0 50.0 66.7
  pT3 40 33.0 41.6 29.2 43.2
  pT4 4 43.0 50.0 50.0 66.7
pN category <0.001 <0.001 0.003
  pN0 39 - 61.1 53.7 67.5
  pN1 14 43.0 40.2 24.5 36.1
  pN2 8 13.0 12.5 0 0
pTNM Stage 0.007 0.005 0.012
  I 11 - 90.9 80.8 80.8
  II 27 43.0 47.6 40.7 65.4
  III 23 26.0 33.5 19.3 26.4
BMM <0.001 <0.001 0.001
  Positive 13 13.0 15.4 7.7 34.2
  Negative 48 66.0 59.7 49.1 60.6
BMM, bone marrow micrometastasis; CI, confidence interval; DDFS, distant disease-free survival; DFS, disease-free survival; MST, median survival time; OS, overall survival.
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The median survival time (MST) of the 61 patients 
was 62.0 months (95% CI 39.4–84.6 months), and the 5-year 
overall survival rate was 50.0%. The MST, 5-year overall 
survival rate, 5-year disease-free survival rate, and 5-year 
distant disease-free survival rate for cases with positive 
BMM were 13.0 months (95% CI 3.6–22.4 months), 15.4%, 
7.7%, and 34.2%, respectively, compared with those of 66.0 
months, 59.7%, 49.1%, and 60.6% for cases with negative 
BMM (p < 0.05). In separate subgroup analysis, the 5-year 
overall survival rate, 5-year disease-free survival rate, and 
5-year distant disease-free survival rate for patients of stage 
I–II disease with negative BMM were 66.4%, 60.5%, and 
74.1%, respectively, compared with those of 20.0%, 0%, and 
20.0% for cases with positive BMM (p < 0.05). The 5-year 
overall survival rate (p = 0.055), 5-year disease-free survival 
rate (p = 0.081), and 5-year distant disease-free survival rate 
(p = 0.235) for patients of stage III disease with negative 
BMM were 45.0%, 22.5%, and 27.5%, respectively, com-
pared with those of 12.5%, 12.5%, and 29.2% for cases with 
positive BMM.
Finally, we assessed the relationship between the clini-
copathologic features and the prognosis of these patients. 
The variables related to overall survival, disease-free sur-
vival, and distant disease-free survival in univariate analysis 
were shown in Table 2.
Histologic grade, pN category, pTNM stage, and BMM 
were found to affect overall survival (p < 0.05), whereas 
only pN category, pTNM stage, and BMM were correlated 
with disease-free survival and distant disease-free survival 
(p < 0.05). In multivariate analysis, BMM were found to be an 
independent factor in the prediction of overall survival (odds 
ratio [OR] 3.928, p = 0.001, Table 3), disease-free survival 
(OR 4.285, p < 0.001, Table 3), and distant disease-free sur-
vival (OR 3.270, p = 0.013, Table 3). pN category was another 
independent factor in the prediction of overall survival and 
disease-free survival (p < 0.05). The patients with BMM were 
more likely to have metastases and a poor survival (Fig. 1).
DISCUSSION
Metastasis is the main cause of death in patients with 
solid epithelial tumors. Many patients will relapse with met-
astatic disease despite the absence of detectable metastases 
at the time of primary surgery.17 It is suggested that dissemi-
nated tumor cells or micrometastases, undetectable by cur-
rent routine methods, may have been present at the time of 
surgery.18,19
Bone marrow is one of the most common organs 
involved by tumors that metastasize through the blood stream. 
20 As the bone marrow does not normally express epithelial 
cell components, detection of the expression of specific epi-
thelial markers in the bone marrow implies the presence of 
metastatic cancer cells. 16 Many studies have used cytokera-
tins (CKs) as the markers, which are regularly and abundantly 
expressed by epithelial cells and their malignant descendents. 
CK19 mRNA has been found to be highly expressed in nor-
mal esophageal epithelium and ESCC,21 so it serves as a good 
marker to detect BMM in the ESCC patients.
Although micrometastases in bone marrow were quite 
frequent in our study group, overt skeletal metastases of 
esophageal cancer cells were observed in only one patient 
during follow-up. It was thought that epithelial cells in bone 
marrow appeared to indicate a transition of the state of tumor 
disease, which could show a general spreading of the primary 
tumor, but not necessarily a metastasization.13
Few studies have examined the clinical significance of 
BMM detected in esophageal cancer. Previous studies have 
shown that BMM detected at the time of surgery was an inde-
pendent risk factor for esophageal cancer patients after short-
term follow-up (<3 years).12,13 To our knowledge, our study is 
the first to evaluate the long-term outcome of BMM in patients 
with ESCC. We have previously reported that ESCC patients 
with BMM have a shorter overall survival and disease-free 
survival after short-term follow-up.16 In the current study, we 
confirm the same results for these patients after a long-term 
follow-up. Moreover, we found that BMM was the only inde-
pendent factor in the prediction of distant disease-free sur-
vival. Gray et al.15 reported the first study on the long-term 
outcome of BMM detected at the time of surgery in operable 
esophageal cancer, but found that BMM did not influence the 
long-term survival. The small sample size (42 patients), the 
different detection methods, and the different histologic types 
of the patients enrolled in their study may have contributed to 
the different results from those in our report.
The clinical or the prognostic significance of BMM 
detection is still a matter of debate. Most published papers 
report an association between the presence of BMM and a 
poor prognosis,5–13 though some other researchers have not 
demonstrated similar associations between BMM positivity 
and poor outcome.22 So far, the most comprehensive micro-
metastasis research has been carried out in breast cancer. A 
meta-analysis with 4703 breast cancer patients showed that 
BMM at the time of diagnosis appeared to be a significant 
and independent predictor of a lower overall survival, breast 
TABLE 3.  Multivariate Cox Regression Analysis in Regard to 
Overall Survival, Disease-Free Survival, and Distant Disease-
Free Survival of the 61 Patients with Esophageal Squamous 
Cell Carcinoma
Prognostic Factor
Odds 
Ratio 95%CI p Value
Overall survival
  Histologic grade 1.315 0.727–2.376 0.365
  pN category 1.880 1.015–3.481 0.045
  pTNM Stage 1.150 0.580–2.284 0.689
  BMM 3.928 1.753–8.802 0.001
Disease-free survival
  pN category 1.962 1.088–3.539 0.025
  pTNM Stage 1.209 0.638–2.291 0.561
  BMM 4.285 1.956–9.386 <0.001
Distant disease-free survival
  pN category 1.832 0.909–3.692 0.091
  pTNM Stage 1.354 0.661–2.998 0.456
  BMM 3.270 1.291–8.287 0.013
CI, confidence interval.
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cancer-specific survival, and distant disease-free survival after 
a median follow-up of 5.2 years.23
No general consensus has been established to standard-
ize the laboratory protocols for micrometastasis detection to 
date. This may be the cause of the differing results in the prog-
nostic prediction of BMM. There are numerous methodolo-
gies available for the study of BMM, so that comparison of 
data between different groups is difficult. Many factors can 
influence the results in the detection of BMM, such as the 
choice of detection methods, the selection of the antibody, the 
number of cells analyzed, and the control specimens.20 It is 
important to establish standard technical procedures of BMM 
detection to achieve consistency between different reports.
Although the TNM stage was the most often used and 
effective parameter to predict the prognosis of patients with 
ESCC, some of the patients at an early stage will experience 
metastatic disease soon after primary therapy. New parame-
ters need to be defined to improve the identification of patients 
at high risk for relapse. In our study, five patients with stage 
I–II diseases were detected with positive BMM. This means 
that BMM may have existed at an early stage of the tumor. 
Moreover, 4 of these 5 patients with positive BMM died dur-
ing follow-up, although only 13 of the 33 patients of stage 
I–II disease with negative BMM died during follow-up, and 
the 5-year overall survival rate, 5-year disease-free survival 
rate, and 5-year distant disease-free survival rate for patients 
with negative BMM were significantly higher than those with 
positive BMM (p < 0.05). This means that the patients of early 
stage but with positive BMM may have a poorer prognosis 
than those with negative BMM. On the other hand, in the 
FIGURE 1. A, Kaplan-Meier curves of overall survival of patients with (BMM+) and without (BMM−) bone marrow microme-
tastasis (BMM). The survival difference was significant (p < 0.001). (B) Kaplan-Meier curves of disease-free survival of patients 
with (BMM+) and without (BMM−) BMM. The survival difference was significant (p < 0.001). (C) Kaplan-Meier curves of distant 
disease-free survival of patients with (BMM+) and without (BMM−) BMM. The survival difference was significant (p = 0.001).
1212 Copyright © 2014 by the International Association for the Study of Lung Cancer
Chen et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 8, August 2014
23 patients with stage III diseases, 7 of the 8 patients with 
positive BMM died during follow-up, whereas only 10 of 
the 15 patients with negative BMM died during follow-up. 
The 5-year overall survival rate, 5-year disease-free survival 
rate, and 5-year distant disease-free survival rate for patients 
with negative BMM were higher than those with positive 
BMM, but the difference did not reach statistical significance 
(p = 0.055), This may be possibly because of the small patient 
numbers in our study. From our research, we found that detec-
tion of BMM in ESCC patients was an independent prognos-
tic factor in the prediction of the subsequent development of 
metastatic disease and disease outcome. So, BMM detection 
may be a useful adjunct to tumor, node, metastasis staging, 
and may facilitate us in the selection of patients with a high 
risk of metastatic spread to receive adjuvant therapy.
We also found that BMM and the pN category were inde-
pendent factors in the prediction of overall survival and disease-
free survival, but only BMM was an independent prognostic 
factor of distant disease-free survival. This may mean that BMM 
detection was more useful in predicting distant metastasis, 
whereas local recurrence may be correlated with pN category.
However, not all patients with BMM will develop meta-
static disease eventually. Some patients with BMM will never 
develop relapse or metastatic disease after long-term follow-
up. This may be because of the biological heterogeneity of 
these disseminated cells in the bone marrow.24,25 According 
to recent observations, some of these cells remain in a dor-
mant state and may never initiate a relapse,26,27 whereas others 
remain in a proliferating state or escape the dormancy control 
mechanisms to enter the cell cycle by still unknown condi-
tions in the microenvironment or by molecular alterations.28
Detection of BMM may help to select patients with a 
higher risk of developing distant metastases. Detection of can-
cer cells in bone marrow at the time of treatment may imply 
systemic tumor dissemination and a metastatic phenotype,2 
which implies that not only local therapy but systemic ther-
apy should be administered to these patients. The fact that in 
our study that majority of the patients with BMM died from 
tumor recurrence indicates that surgical resection alone was 
not enough for these patients.
Neoadjuvant chemoradiotherapy is now the stan-
dard treatment for esophageal cancer patients with a locally 
advanced stage, and it has shown a significant survival ben-
efit.29 Thus far, the influence of neoadjuvant chemoradiother-
apy on esophageal cancer patients with BMM has not been 
thoroughly investigated. Further investigations regarding the 
effect of systemic therapy, especially neoadjuvant chemora-
diotherapy, on these patients with BMM are necessary.
In conclusion, BMM is an independent prognostic factor 
in the prediction of the subsequent development of metastatic 
disease and disease outcome for ESCC patients. Patients with 
BMM have significantly shorter overall survival, disease-free 
survival, and distant disease-free survival. BMM detection 
may be a useful adjunct to conventional tumor-staging tech-
niques that will improve clinical management of patients with 
ESCC in the future. Further prospective studies are required to 
examine our findings and to evaluate the value of neoadjuvant 
or adjuvant systemic therapy in ESCC patients with BMM. 
Further studies are also needed to develop standardized tech-
niques for BMM detection.
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